TY - JOUR
T1 - Remarkable selectivity of the in vivo binding of [3H]Ro15-4513 to α5 subtype of benzodiazepine receptor in the living mouse brain
AU - Momosaki, Sotaro
AU - Hosoi, Rie
AU - Abe, Kohji
AU - Inoue, Osamu
PY - 2010/12
Y1 - 2010/12
N2 - To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50% of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.
AB - To evaluate the binding characteristics of [3H]Ro15-4513 with the central benzodiazepine (BZ) receptor, inhibition experiments of [3H]Ro15-1788 and [3H]Ro15-4513 were performed both in vitro and in vivo, using two BZ ligands, flunitrazepam (FNP), and ethyl-β-carboline-3-carboxylate (β-CCE). FNP inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in a dose-dependent manner in the mouse cerebral cortex, hippocampus, and cerebellum, both in vitro and in vivo. β-CCE also inhibited the binding of [3H]Ro15-1788 and [3H]Ro15-4513 in all the aforementioned brain regions in vitro. However, in vivo, β-CCE inhibited the binding of [3H]Ro15-4513 in the cerebral cortex and cerebellum, but not in the hippocampus, even at an injected dose of up to 1mg/kg. In contrast, more than 50% of the in vivo binding of [3H]Ro15-1788 was inhibited by 1 mg/kg of β-CCE in all regions. The time-activity curve of [3H]Ro15-4513 in the hippocampus also showed no alteration of the peak uptake between the control group and 0.3 mg/kg of β-CCE coinjected group. These results indicated that the binding characteristics of [3H]Ro15-4513 with the BZ receptor differed markedly between the in vitro and in vivo condition, and the selectivity of [3H]Ro15-4513 binding to α5 subtype of BZ receptor in the mouse brain seemed to be remarkable under the in vivo condition.
KW - GABA/BZ receptor
KW - In vivo
KW - Ro15-4513
KW - α5 subtype
KW - β-CCE
UR - http://www.scopus.com/inward/record.url?scp=77958161142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958161142&partnerID=8YFLogxK
U2 - 10.1002/syn.20812
DO - 10.1002/syn.20812
M3 - Article
C2 - 20506503
AN - SCOPUS:77958161142
VL - 64
SP - 928
EP - 936
JO - Synapse
JF - Synapse
SN - 0887-4476
IS - 12
ER -